Successful treatment in pulmonary alveolar proteinosis with the combination of intravenous immunoglobulin and pulse methylprednisolone

2007 ◽  
Vol &NA; ◽  
pp. S220-S221
Author(s):  
Nongnapa Jirarattanasopa ◽  
Tantikul Chutsumarn ◽  
Orathai Jirapongsananuruk ◽  
Nualanong Visitsunthorn ◽  
Pakit Vichyanond
Respirology ◽  
2006 ◽  
Vol 11 (s1) ◽  
pp. S74-S77 ◽  
Author(s):  
Kazutoshi CHO ◽  
Koh NAKATA ◽  
Tadashi ARIGA ◽  
Satoru OKAJIMA ◽  
Tadashi MATSUDA ◽  
...  

2016 ◽  
Vol 17 ◽  
pp. 641-645 ◽  
Author(s):  
Mirjana Trukalj ◽  
Marija Perica ◽  
Željko Ferenčić ◽  
Damir Erceg ◽  
Marta Navratil ◽  
...  

2017 ◽  
Vol 24 (2) ◽  
pp. 232-236
Author(s):  
Virginija Šileikienė ◽  
Vygantas Gruslys ◽  
Ingrida Zeleckienė ◽  
Rolandas Zablockis ◽  
Robertas Samalavičius ◽  
...  

2021 ◽  
Vol 49 (4) ◽  
pp. 030006052110100
Author(s):  
Shenyun Shi ◽  
Rujia Wang ◽  
Ling Chen ◽  
Yan Li ◽  
Yingwei Zhang ◽  
...  

Pulmonary alveolar proteinosis (PAP) is a rare disorder characterized by the accumulation of excessive surfactant lipids and proteins in alveolar macrophages and alveoli. Oral statin therapy is a novel treatment for PAP with hypercholesterolemia. However, this treatment has never been described in a patient without hypercholesterolemia. Here, we present a case of successful treatment with atorvastatin for a patient with possibly unclassified PAP without hypercholesterolemia who responded poorly to whole lung lavage therapy and inhaled granulocyte-macrophage colony-stimulating factor. After 18 months of atorvastatin treatment, the patient experienced improvements in dyspnea, radiographic abnormalities and pulmonary function. The present case study supports the feasibility of statin therapy for PAP regardless of the level of cholesterol.


Sign in / Sign up

Export Citation Format

Share Document